Skip to main content

Advertisement

Table 2 Methylation marker performance by clinical findings, including selected sub-categories

From: Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia

Most advanced findings No. (%) Positivity Counts (%); 95 % CI  
BCAT1 IKZF1 Either marker OR (95 % CI)1 X 2
ALL CASES 2101 181 (9); 8-10 89 (4); 3-5 204 (10); 8-11   
Cancer 129 (6) 74 (57); 48 - 66 62 (48); 39 - 57 85 (66); 57 - 74 34 (20 - 59)** 241**
 Stage I 29 (22) 7 (24); 10 - 44 8 (28); 13 - 47 11 (38); 21 - 58 11 (5 - 26)** 43**
 Stage II 42 (33) 26 (62); 46 - 76 17 (40); 26 - 57 29 (69); 53 - 82 40 (18 - 86)** 16**
 Stage III 40 (31) 27 (68); 51 - 81 22 (55); 38 - 71 29 (73); 56 - 85 47 (21 - 105)** 172**
 Stage IV 16 (12) 13 (81); 54 - 96 15 (94);70 - 100 15 (94);70 - 100 266 (34-2101)** 158**
 Unstaged 2 (2) 1 (50); 1 - 99 0 (0); 0 - 80 1 (50); 1 - 99 18 (1 - 293)** 8*
 Early Stage (I + II) 71 (55) 33 (46); 35 - 59 25 (35); 24 - 47 40 (56); 44 - 68 23 (12 - 43)** 148**
 Late Stage (III + IV) 56 (43) 40 (71); 58 - 83 37 (66); 52 - 78 44 (79); 66 - 88 65 (30 - 139)** 230**
Adv. adenoma2 338(16) 16 (5); 3 - 8 7 (2); 1 - 4 20 (6); 4 - 9 1.1 (0.6 - 2) 0.1
 HGD 32 (9) 2 (6); 1 - 21 1 (3); 0.1 - 16 2 (6); 0.1 - 21 1.2 (0.3 - 5) 0.1
 TVA3 144(43) 7 (5); 2 - 10 0 (0); 0 - 20 7 (5); 2 - 10 0.9 (0.4 - 2) 0.1
 ≥10mm4 107(32) 3 (3); 1 - 8 4 (4); 1 - 9 5 (5); 2 - 11 0.9 (0.3 - 2) 0.1
 ≥3 TAs (<10mm) 34 (10) 4 (12); 3 - 27 0 (0); 0 - 10 4 (12); 3 - 27 2.4 (1 - 7) 2.4
Serrated Adenoma 19 (6) 0 (0); 0 - 20 2 (11); 2 - 52 2 (11); 2 - 52 2 (0.5 - 10) 0.9
Non adv. adenoma 346(16) 23 (7); 4 - 10 2 (1); 0.1 - 2 23 (7); 4 - 10 1.3 (0.7 - 2) 0.6
No neoplasia 838(40) 46 (6); 4 - 7 15 (2); 1 - 3 52 (6); 5 - 8 1.2 (0.7 - 2) 0.4
 IBD5 61 (3) 3 (5); 1 - 14 0 (0); 0 - 6 3 (5); 1 - 14 0.9 (0.3- 3) 0.01
 Non neoplastic polyps6 296(14) 16 (5); 3 - 9 4 (2); 0.4 - 4 18 (6); 4 - 9 1.1 (0.6 - 2) 0.2
 Hemorrhoids 288(60) 14 (5); 3 - 8 6 (2); 1 - 4 16 (6); 3 - 9 1.0 (0.5 - 2) 0.02
 Angiodysplasia 11 (0.5) 2 (18); 2 - 52 0 (0); 0 – 28 2 (18); 2 - 52 4 (1 -19) 3
 Diverticular disease 182(38) 11 (6); 3 - 11 5 (3); 1 - 6 13 (7); 4 - 12 1.3 (0.7 - 3) 0.8
Normal colon/rectum 450(21) 22 (5); 3 - 7 3 (1); 0 - 2 24 (5); 3 - 8 1 1
  1. 1Calculation of Odds Ratios (OR) or Chi-square (X2) values against normal colon/rectum; *P-values <0.05, **P-values <0.001; 2Advanced adenoma including Stage 0 cancers; 3Excluding HGD; 4no HGD or TVA; 5Inflammatory bowel disease 6Hyperplastic, unspecified and other polyps
  2. HGD high-grade dysplasia, TVA tubulovillous adenoma, TA tubular adenoma, IBD inflammatory bowel disease